VICH Task Force for Efficacy Studies for Combination Products Progress Report (Final) VICH members JMAFF (chair)K. Noda JVPAE. Oishi IFAH-EUM. Bobey EUK.

Slides:

Advertisements

Similar presentations

OIE First Global Conference on Veterinary Legislation 1 Control of Veterinary Products: The Need for Global Standards Merton V. Smith, Ph.D., J.D. Director,

Advertisements

Foundations of Regulation

Research & Innovation Evolution from IMI1 to IMI2: challenges ahead Elmar Nimmesgern, PhD DG Research & Innovation 1.

Merton V. Smith, Ph.D., J.D. Director International Programs Center for Veterinary Medicine U.S. Food and Drug Administration Governance of Veterinary.

Sustainable Energy Systems Int’l H 2 Safety Conf, Pisa, Italy, 8-10 Sep IPHE projects focus on pre-competitive collaborative research, development.

Effectiveness Evaluation for Therapeutic Drugs for Non-Food Animals

TANZANIA August Note on Choice of Comparator Products: Current status Note to Applicants on Choice of Comparator Products in the Prequalification.

Training Workshop on Pharmaceutical Development with a Focus on Paediatric Medicines / October |1 | Regulatory Requirement on Dossier of Medicinal.

Good Clinical Practice GCP

Simon Brewin Overview of the National Supply Chain Reform Task Force.

Overview of ICH Procedures July 2015

Artemisinin combined medicines, Kampala, February |1 | Training workshop on regulatory requirements for registration of Artemisinin based combined.

Review of the Gothenburg Protocol: WGSR Conclusions Review of the Gothenburg Protocol: WGSR Conclusions 8th Joint TFEIP/EIONET Meeting Dublin, October.

WHO Workshop on Assessment of Bioequivalence Data Addis Ababa, 31. August – 3. September 2010 Selection of comparators Compiled by Jan Welink WHO Workshop.

EC actions against the rising threats from Antimicrobial Resistance

Work Prioritization Model (WPM) Team Status Update Olga Cavalli Chair – WPM Team 10 March 2010 Presented to: GNSO Council.

Session VII WEIGHING IN ON MICROBIOLOGICAL ADI: EXPERIENCES AND PERSPECTIVES Introduction October 26, 2012.

FDA Advisory Committee for Pharmaceutical Science and Clinical Pharmacology July 22-23, 2008 Introduction and Update Helen N. Winkle Director, Office of.

Role of VICH and VICH guidelines in the approval process for veterinary medicinal products David Mackay, European Medicines Agency VICH Workshop – Dar.

Application of VICH GLs – extract from group discussion General: VICH GLs do not prescribe the data package to be submitted for registration, they merely.

JMAFF (Chair of Biologicals Quality Monitoring EWG)

VICH General Principles and current update of VICH Outreach Forum activity 1.

VICH Training Strategy Steven D. Vaughn, DVM Director, Office of New Animal Drug Evaluation, Center for Veterinary Medicine U.S. Food and Drug Administration.

VICH Task Force for Efficacy Studies for Combination Products Progress Report for the 32 th SC /6 th VOF meeting (Final)

Regulatory Overview of Complementary Medicines in South Africa Dr A T Sigobodhla Session : VICH Outreach Forum Tokyo, Japan: 26 – 27 October 2015.

Introduction to the VICH Outreach Forum Steven D. Vaughn, DVM VICH Workshop Dar Es Salaam, Tanzania – June 24, 2015.

-What is VICH, History and Objectives Hervé MARION, DVM VICH Secretariat.

1 VICH AND VETERINARY MEDICINES AVAILABILITY VICH5 CONFERENCE, OCTOBER 2015, TOKYO VICH AND VETERINARY MEDICINES AVAILABILITY VICH5 CONFERENCE, OCTOBER.

VICH Outreach Forum Stability Studies to address climatic zones III and IV Mai Huynh US FDA/Center for Veterinary Medicine October 26-27, 2015.

Session 3: How to use VICH GLs VICH5 Conference, October 2015, Tokyo 1.

An agency of the European Union Principles for the assessment and authorisation of antimicrobials in the EU VICH Outreach Forum, October 2015 Presented.

Introduce GLP/GCP into China Shixin XU, PhD, Prof. China IVDC.

The Benefits of VICH to VICH Member Countries and Regions DONALD A. PRATER, DVM Director, U.S. FDA Europe Office Office of International Programs Office.

1 NDPHS Northern Dimension Partnership in Public Health and Social Well-being Decent work and health for all Expert Group SIHLWA, Helsinki, May 2007.

VICH Outreach Forum OIE contribution 2 nd meeting of the Forum members Washington, 19 – 20 February 2013 S. Munstermann, JP Orand, C. Lambert.

Challenges of Developing VICH Guidance for Residue Studies in Food Producing Aquatic Species Pamela Boner, Zoetis Session 7: VICH Conference Tokyo, Japan:

New data collection-State of play Residues of Veterinary Medicinal Products in live animals and animal products Anca Stoicescu, Scientific Officer Zagreb,

Link between legal framework of VMP regulation and VICH GLs in Japan Takashi Kozasa DVM Ministry of Agriculture, Forestry and Fisheries Government of Japan.

Session 9: The Vision for the Future 1 Dr. Yuko Endo JMAFF.

Session 7: VICH Conference

How to comment VICH guidelines Shixin XU, PhD, Prof. China IVDC.

Work Prioritization Model (WPM) Team Status Update Olga Cavalli Chair – WPM Team ?? March 2010 Presented to: GNSO Council.

1 THE OIE REPORT 32 nd VICH SC Meeting / 6 th VICH Outreach Forum Meeting Jean-Pierre Orand, Anses, France, OIE Collaborating Centre.

How to get involved in VICH Dr. Allen Bryce Independent consultant Canberra, Australia VICH Workshop: Dar Es Salaam, Tanzania – 24.

1 1 Topics “out of the scope of VICH” Brigitte Boenisch IFAH-Europe 2 nd VICH Outreach Forum Meeting Washington, 19 th /20 th February 2012 – how and by.

1 The contribution of VICH to the global One Health approach VICH5 CONFERENCE, OCTOBER 2015, TOKYO Jean-Pierre Orand, Anses, France, OIE Collaborating.

ISO/HL Specification: Individual Case Safety Report (ICSR) Release 2 Lise Stevens Data Standards Project Manager FDA CBER/ADRM Bioinformatics Support.

Issues Batch safety testing for vaccines

Update of Results of the Survey on training Priorities

Hervé Marion, DVM VICH Secretariat

VICH General Principles and

Pre-Investigational New Drug (pre-IND) Meeting with FDA

The OIE report 30th VICH SC Meeting / 4th VICH Outreach Forum Meeting

The Vision for the Future

Report by the VICH Steering Committee on issues raised by Forum members during the 1st Outreach Forum meeting Hervé Marion, DVM VICH Secretariat.

Data Requirements for Old Products/Generics, Bioequivalence

World Health Organization

Waiving Target Animal Batch Safety Testing for vaccines

education and training systems (UOE)

The expectations from VICH Outreach Forum members

How Can I Get More Information on VICH?

The Benefits of VICH to Emerging Countries

Meeting of the Working Group “Cultural statistics”

Activities of the UNECE-UNODC Task Force on Victimization Surveys

Introduction. Presentation of the mandate of the Task Force

Green Infrastructure: Working method

Quality guidelines on impurities

GL8 (R) – Stability testing for medicated premixes

Task Force Peer reviews and quality Eurostat

Hervé Marion, DVM VICH Secretariat

Presentation transcript:

VICH Task Force for Efficacy Studies for Combination Products Progress Report (Final) VICH members JMAFF (chair)K. Noda JVPAE. Oishi IFAH-EUM. Bobey EUK. Healey US FDAC. Groesbeck AHIB. McKusick Observer South Africa, Nat. Dept. healthV. Naidoo VOF members China PR, IVDCS. Xu Argentina, SENASAL. Sbordi Taiwan, Council of AgricultureT-R. Jan UEMOAK.Th. Domagni CAMEVETL. Sbordi Additional contributors Australia, APVMAP. Reeves NZ, Min. Primary IndustryW. Hughes

Introduction  At the 3 rd VOF meeting in Nov 2013, China PR presented a Concept Paper for a VICH guideline on “efficacy studies for combination drug products”.  The SC & VOF members welcomed the proposal confirming that it is an important topic where guidance is currently lacking.  The scope of this topic is very broad and could lead to several GLs.  It would be useful to identify the different combinations available in order to reach agreement on which GLs should be developed. The SC decided to create a task force (TF) chaired by JMAFF.

Mandate  To elaborate a discussion paper proposing a more focused scope for the development of a VICH GL for efficacy studies for combination products.  The TF will  Prioritize the target products  Explore the possibility of a general policy document >Explore Major combination >Analyse GLs already in Place

Major Combination-products

TitleCategoryScope EU Guidance on pharmaceutical fixed combination products General EU data requirements for efficacy, safety and residues documentation for veterinary medicinal products, containing 2 or more active substances. US CVM GFI #24 Drug Combinations for Use in Animals General Information and data to demonstrate that the combination of drugs provides a benefit that cannot be obtained by the use of each of the drugs individually Aust. WAAVP guideline: (Adopted as National GL in Australia) Anthelmintic combination products targeting nematode infections of ruminants and horses Antiparasitics A scientific basis for the approval Anthelmintic products with two or more constituents with similar spectra of activity from different pharmacological classes For use in addition to the existing requirements/GLs for single-API products. Technical Requirement GLs in Place WAAVP: World Association for Advancement of Veterinary Parasitology

Conclusion  General combination GL  EU and US are the representative General GLs.  Internationally harmonized GL by extracting appropriate elements from them.  Specific combination GL  Main target : Anti-Parasitics  Drug resistance control will be a main objective.  Inclusion of WAAVP/Australian GL into VICH framework should be explored in collaboration with the Anthelmintics-EWG.  Other specific combination may be a target in the future.  After some experiences  Further discussion by the VOF and SC members needed

Thank you 感謝